Nektar Therapeutics (NASDAQ:NKTR) Director R Scott Greer sold 10,000 shares of the stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $67.39, for a total transaction of $673,900.00. Following the completion of the transaction, the director now directly owns 140,333 shares in the company, valued at $9,457,040.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Nektar Therapeutics stock traded down $2.65 during mid-day trading on Friday, hitting $59.25. 2,085,740 shares of the stock were exchanged, compared to its average volume of 1,643,916. The company has a debt-to-equity ratio of 0.13, a quick ratio of 19.55 and a current ratio of 19.67. Nektar Therapeutics has a 12 month low of $21.11 and a 12 month high of $111.36. The firm has a market cap of $10.84 billion, a price-to-earnings ratio of 12.67 and a beta of 2.27.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported $5.33 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.11. The company had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.03 billion. Nektar Therapeutics had a net margin of 65.69% and a return on equity of 174.70%. Nektar Therapeutics’s revenue for the quarter was up 3043.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.39) EPS. equities research analysts predict that Nektar Therapeutics will post 3.77 EPS for the current fiscal year.

NKTR has been the topic of several research reports. HC Wainwright downgraded shares of Nektar Therapeutics from a “buy” rating to a “neutral” rating and set a $54.00 price target on the stock. in a research note on Monday, June 11th. Cowen reiterated a “buy” rating and set a $86.00 price objective on shares of Nektar Therapeutics in a research note on Thursday, August 9th. ValuEngine upgraded shares of Nektar Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, August 28th. William Blair reiterated a “buy” rating on shares of Nektar Therapeutics in a research note on Monday, June 4th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Nektar Therapeutics from $90.00 to $78.00 and set an “overweight” rating on the stock in a research note on Monday, June 4th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $82.91.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Asset Management One Co. Ltd. acquired a new stake in shares of Nektar Therapeutics during the first quarter worth about $110,000. Daiwa Securities Group Inc. bought a new position in shares of Nektar Therapeutics in the 1st quarter worth $111,000. We Are One Seven LLC bought a new position in shares of Nektar Therapeutics in the 1st quarter worth $118,000. Livforsakringsbolaget Skandia Omsesidigt bought a new position in shares of Nektar Therapeutics in the 2nd quarter worth $137,000. Finally, Flagship Harbor Advisors LLC bought a new position in shares of Nektar Therapeutics in the 2nd quarter worth $142,000. 92.22% of the stock is owned by institutional investors and hedge funds.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.

Featured Article: Find a Trading Strategy That Works

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.